RNTX · Rein Therapeutics, Inc.

$0.78 -0.01 (-0.98%) At close · Jul 27

Market Cap

$67.69M

85.54M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Brian Windsor	CEO	$575,000	$287,500	—	—	—	$20,195	$882,695
Timothy M. Cunningham	CFO	$433,940	—	—	—	—	—	$433,940

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Manuel C. Alves Aivado	CFO	$115,960	—	—	$227,696	—	$998,262	$1,331,919
Brian Windsor	CEO	$506,250	$227,812	—	$24,739	—	$19,358	$778,159
Charles T. Garner	Former principal financial officer and principal accounting officer	$168,750	—	—	—	—	$307,211	$475,961
Timothy M. Cunningham	CFO	$275,600	—	—	—	—	—	$275,600

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Manuel C. Alves Aivado	CFO	$587,336	—	—	—	—	$43,399	$630,735
D. Allen Annis	Senior Vice President, Research	$141,176	—	—	—	—	$404,972	$546,148
Brian Windsor	CEO	$85,256	$204,375	—	—	—	$10	$289,642
Charles T. Garner	Former principal financial officer and principal accounting officer	—	—	—	—	—	—	—

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Manuel C. Alves Aivado	CEO	$587,336	—	—	$543,850	—	$113,234	$1,244,420
D. Allen Annis	Senior Vice President, Research	$404,100	—	—	$150,250	—	$17,914	$572,264
Vojislav Vukovic	Senior Vice President, Chief Medical Officer	$248,566	—	—	$72,010	—	$225,127	$545,703

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Manuel C. Alves Aivado	CEO	$564,736	$254,131	—	$2,368,000	—	$93,512	$3,280,379
Richard J. Wanstall	CFO	$402,270	$194,817	—	$582,295	—	$17,648	$1,197,030
Vojislav Vukovic	Senior Vice President, Chief Medical Officer	$423,225	$133,316	—	$388,197	—	$17,648	$962,386

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Manuel C. Alves Aivado	CEO	$507,400	$475,700	—	$182,200	—	$73,158	$1,238,458
Vojislav Vukovic	Senior Vice President, Chief Medical Officer	$405,000	$265,250	—	$102,488	—	$6,192	$778,930
Richard J. Wanstall	CFO	$330,000	$215,500	—	$163,406	—	$6,192	$715,098

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Manuel C. Alves Aivado	CEO	$507,400	—	—	$597,634	—	$73,031	$1,178,065
Vojislav Vukovic	Senior Vice President, Chief Medical Officer	$405,000	—	—	$239,651	—	$6,192	$650,843
Donald V. Dougherty	CFO	$260,525	—	—	$179,290	—	$129,923	$569,738
D. Allen Annis	Senior Vice President, Research	$325,000	—	—	$179,290	—	$6,192	$510,482
Richard J. Wanstall	CFO	$292,000	—	—	$103,250	—	$6,192	$401,442

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Manuel C. Alves Aivado	CEO	$441,592	$164,549	—	$789,578	—	$67,986	$1,463,705
Donald V. Dougherty	CFO	$357,100	$99,988	—	—	—	$6,192	$463,280
Vojislav Vukovic	Senior Vice President, Chief Medical Officer	$64,614	$20,144	—	$223,459	—	$128,748	$436,965
D. Allen Annis	Senior Vice President, Research	$285,960	$94,754	—	—	—	$6,192	$386,906

Key facts CIK 1420565 CUSIP 00887A204 13F (30d) 6 filings 6 filers Visit website